CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
未选择的供者来源造血干细胞输注可减轻 CAR-T 细胞相关血液毒性
英文原题：Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity.
查看英文原题
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
既往接受过异基因干细胞移植的患者在接受嵌合抗原受体-T细胞治疗后出现的血液学毒性，通过输注未经选择的供者来源干细胞增强剂得以解决。由于供者淋巴细胞的作用，患者出现了控制良好的急性移植物抗宿主病发作。
展开英文摘要原文
Hematological toxicity following Chimeric Antigen Receptor-T therapy in a patient with a prior allogeneic stem cell transplantation was resolved by the infusion of unselected donor-derived stem cell boost. Due to the donor's lymphocytes, the patient experienced a well-controlled flare-up of acute graft versus host disease.
论文信息
- 作者
- Galli E、Limongiello MA、Metafuni E、Giammarco S、Fresa A、Piccirillo N、Bianchi M、Laurenti L
- 单位
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Italy
- 文献类型
- 读者来信
- 期刊
- American journal of hematology2024 Apr
- 原文标识
- PubMed 38247313 · DOI 10.1002/ajh.27208